Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
A phase 1/2 trial of Patritumab deruxtecan, Trastuzumab, Pertuzumab and Tucatinib in HER2-positive breast cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) is a phase 1/2 interventional study registered as NCT06686394 by Merck Sharp & Dohme LLC, with 81 participants planned, started 2025-02-26 and due to reach its primary completion in 2030-04-18. Interventions recorded: Patritumab deruxtecan, Trastuzumab, Trastuzumab Biosimilar, Pertuzumab and Tucatinib.
Similar pages
not linked directly; found by shared links- TrialA Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
Shares Tucatinib, Pertuzumab, Daiichi Sankyo, HER2-positive breast cancer and the tag pipeline.
- TrialStudy of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
Shares Patritumab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
- TrialA Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Shares Patritumab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
- TrialStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer and the tag pipeline.
- TrialA Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Shares Patritumab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
- TrialStudy of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Shares Daiichi Sankyo, Trastuzumab, Merck & Co. (MSD) and the tag pipeline.
- TrialA Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer and the tag pipeline.
- TrialA Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Shares Patritumab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.